Products - Diabetes | Topic

Showing 13 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Diabetic retinopathy: management and monitoring (NG242)
Product type:
Guidance
Programme:
NICE guideline
Published:
13 August 2024
Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes (IPG787)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
16 May 2024
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 March 2024
Insulin icodec for treating type 2 diabetes [ID6175]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
21 May 2025
Type 2 diabetes in adults: management (medicines update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
19 June 2025
Teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of developing the condition ID6259
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ranibizumab port delivery system for treating diabetic macular oedema ID6137
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Aflibercept for untreated diabetic macular oedema TS ID 10621
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Empagliflozin for treating type 2 diabetes in people aged 10 to 17 [ID6258]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
AI in retinal scanning MT524 (MIB265)
Status:
Topic selection
Programme:
Medical technologies guidance
Expected publication date:
TBC
d-NAV for optimization of personal insulin management in adults with type 2 diabetes (MT696)
Status:
Topic selection
Programme:
Medical technologies guidance
Expected publication date:
TBC
PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes, (MT740)
Status:
Topic selection
Programme:
Diagnostics guidance
Expected publication date:
TBC
Basal insulin icodec–semaglutide for treating type 2 diabetes inadequately controlled with daily basal insulin TSID 11940
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Diabetes Products

Filter

Product type
1 selected

Guidance programme

Status

New and updated
1 selected

Showing 13 products

Diabetic retinopathy: management and monitoring (NG242)

Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes (IPG787)

Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)

Insulin icodec for treating type 2 diabetes [ID6175]

Type 2 diabetes in adults: management (medicines update)

Teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of developing the condition ID6259

Ranibizumab port delivery system for treating diabetic macular oedema ID6137

Aflibercept for untreated diabetic macular oedema TS ID 10621

Empagliflozin for treating type 2 diabetes in people aged 10 to 17 [ID6258]

AI in retinal scanning MT524 (MIB265)

d-NAV for optimization of personal insulin management in adults with type 2 diabetes (MT696)

PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes, (MT740)

Basal insulin icodec–semaglutide for treating type 2 diabetes inadequately controlled with daily basal insulin TSID 11940

Diabetes Products

Filter

Product type1 selected

Guidance programme

Status

New and updated1 selected

Showing 13 products

Product type
1 selected

New and updated
1 selected